BioNTech partners with CEPI to advance development of mpox vaccine
WHTC 1450 Holland· 5 days ago(Reuters) -Germany's BioNTech said on Monday it is entering into a partnership with the Coalition ...
BioNTech and CEPI to partner to advance an mRNA-based Mpox vaccine
Market Watch· 5 days agoand the Norwegian-based Coalition for Epidemic Preparedness Innovations, or CEPI, said Monday they...
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI's...
Benzinga· 5 days agoBioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness ...
Another deadly Nipah virus outbreak: What are the symptoms?
New York Post· 5 days ago“This isn’t the stuff of science fiction,” Dr. Richard Hatchett, of the Coalition for Epidemic ...
BioNTech wins up to $90 million in funding for mpox vaccine development
Reuters via AOL· 5 days agoThe vaccine candidates are based on the same messenger-RNA (mRNA) technology which has been used in...
BioNTech partnering with CEPI on monkeypox vaccine development
Seeking Alpha· 5 days agoBioNTech will work with the Coalition for Epidemic Preparedness Innovations on the development ...
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
Morningstar· 2 days agoProduct sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited from a continued recovery of the travel industry as well